Emergent BioSolutions: Anthrax trials

The registry lists 17 Anthrax studies with Emergent BioSolutions as lead sponsor. 5 are open to participants now and 8 have results posted.

Phase 1 5Phase 2 4Phase 3 2Phase 4 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
• Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
• A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
• Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
• Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
• Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 2Results posted
• VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 3Results posted
• Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 4Results posted
• A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 2Results posted
• Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 2Results posted
• Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 3Results posted
• Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 1Results posted
• Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/2Results posted
• A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 1
• BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT01653392
• Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 1
• Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 1